Moleculin Biotech announced that data on its lead drug candidate, annamycin, will be presented at the 2026 ASCO Annual Meeting. The poster highlights a pooled analysis demonstrating annamycin's cardiac safety even at high cumulative doses of anthracyclines, a class of chemotherapy drugs known for cardiotoxicity. This supports annamycin's potential as a safer alternative for treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The presentation at a major oncology conference underscores the drug's progress as Moleculin advances its Phase 3 clinical trial, MIRACLE, aiming for regulatory approval.
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
The global warehouse shuttle software market is projected to grow from $1.57 billion in 2026 to $2.66 billion by 2030, with a CAGR of 14.1%. Growth is fueled by rising e-commerce, warehouse automation, AI-driven orchestration, and robotic material ha...
